Ticlopidine Property

Melting point:

210-212 °C

Boiling point:

117-120 °C(Press: 0.5 Torr)

Density 

1.273±0.06 g/cm3(Predicted)

storage temp. 

2-8°C(protect from light)

solubility 

Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)

form 

Solid

pka

7.10±0.20(Predicted)

color 

Off-White to Pale Yellow

CAS DataBase Reference

55142-85-3(CAS DataBase Reference)

NIST Chemistry Reference

Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro-(55142-85-3)

EPA Substance Registry System

Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro- (55142-85-3)

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H315Causes skin irritation

H319Causes serious eye irritation

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

P332+P313IF SKIN irritation occurs: Get medical advice/attention.

P337+P313IF eye irritation persists: Get medical advice/attention.

Ticlopidine Chemical Properties,Usage,Production

Originator

Ticlid,Millot,France,1978

Uses

Ticlopidine is an antiplatelet drug for the treatment of ischemic heart diseases.

Uses

Ticlopidine suppresses aggregation of thrombocytes and possesses antiaggregant activity. It is believed that its action is connected to its effect on thrombocyte membranes and the reduction in quantity of released adenosine diphosphate and serotonin, which facilitate aggregation of thrombocytes. In wide-ranging clinical trials, ticlopidine presented a number of advantages compared to aspirin.

Definition

ChEBI: A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Manufacturing Process

A solution of thieno[3,2-c]pyridine (13.5 g; 0.1 mol) and 2-chlorobenzyl chloride (17.7 g) in acetonitrile (150 ml) is boiled during 4 hours. After evaporation of the solvent, the solid residue consists of 5-(2- chlorobenzyl)-thieno[3,2-c]pyridinium chloride which melts at 166°C (derivative n° 30). This compound is taken up into a solution comprising ethanol (300 ml) and water (100 ml). Sodium borohydride (NaBH4)(20 g) is added portionwise to the solution maintained at room temperature. The reaction medium is maintained under constant stirring during 12 hours and is then evaporated. The residue is taken up into water and made acidic with concentrated hydrochloric acid to destroy the excess reducing agent. The mixture is then made alkaline with ammonia and extracted with ether. The ether solution is washed with water, dried and evaporated. The oily residue is dissolved in isopropanol (50 ml) and hydrochloric acid in ethanol solution is then added thereto.
After filtration and recrystallization from ethanol, there are obtained 5-(2- chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride crystals (yield: 60%) having a melting point (Koefler block) of 190°C.

brand name

4-c-32 53-32-c;Aplaquette;Derivatives;Klodin;Opteron;Panaldine;Tcp;Ticlidan;Ticlodix;Ticlodone;Ticlopedine;Ticlosan;Tiklid;Tiklyd;Tilcid.

Therapeutic Function

Platelet aggregation inhibitor

World Health Organization (WHO)

Ticlopidine, an inhibitor of platelet aggregation, was introduced in 1978 for use as an antithrombotic agent. By 1982 its use had been associated with cases of agranulocytosis, severe leucopenia and impaired haemostasis. The drug remains available in most countries in which it was approved with appropriate warnings in the product information.

General Description

Ticlopidine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno [3,2-c]pyridine hydrochloride(Ticlid), is useful in reducing cardiac events in patients withunstable angina and cerebrovascular events in secondaryprevention of stroke. It belongs to the thienopyridine classand facilitated the development of clopidogrel. One of thedrawbacks to this agent is its side effect profile, whichincludes neutropenia, and patients receiving this antithromboticshould have their blood levels monitored. Its mechanismof action is similar to that of clopidogrel, in that itinhibits the purinergic receptors on platelets.

Synthesis

Ticlopidine, 5-(o-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine (24.2.1), is synthesized in many different ways. The first way consists of N-alkylation of 4,5,6,7-tetrahydrothieno[3,2-c]pyridine with 2-chlorobenzylchloride.